By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors DUTT, Chaitanya; CHAUTHAIWALE, Vijay; GUPTA, Ram; ZAMBAD, Shitalkumar; DESHPANDE, Shailesh; KOTECHA, Jignesh; GUPTA, Ramesh; SRIVASTAVA, Sanjay; CHHIPA, Laxmikant; ABRAHAM, Jaya, filed on May 12, 2014, was made available online on May 12,
WESTON- AbbVie, a research-based biopharmaceutical company, and Biogen late Friday announced that the U.S. Food and Drug Administration or FDA approved ZINBRYTA, a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis or RMS. The FDA approval of ZINBRYTA is primarily based on results from two clinical
-AstraZeneca today announced positive results from the Phase III FALCON trial. Sean Bohen, Executive Vice President, Global Medicines Development and Chief. Medical Officer at AstraZeneca, said: "The FALCON results bring us closer to.
By a News Reporter-Staff News Editor at Marketing Weekly News BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. announced the signing of a licensing agreement under which BDSI is granting the exclusive rights to develop and commercialize ONSOLIS in the U.S. to Collegium. Under terms of the agreement, Collegium will be...
CAMBRIDGE, Mass.& NORTH CHICAGO, Ill. The U.S. Food and Drug Administration approved ZINBRYTA TM, a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis, Biogen and AbbVie announced today. Clinical data showed ZINBRYTA significantly reduced relapses and brain lesions for up to three years compare
Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the U.S. Food and Drug Administration has granted accelerated approval to Ocaliva for the treatment of primary biliary cholangitis, previously know
Sawai Pharmaceutical is gearing up to sell generic drugs in the U.S., carrying out a strategy shift that makes the huge American market a central pillar of the company's long-term growth plans. The U.S. generic-drug market is estimated at $91 billion, 10 times the annual market in Japan. The company intends to formulate pitavastatin and the three o
By a News Reporter-Staff News Editor at Marketing Weekly News Highland Therapeutics Inc. announced that its U.S. subsidiary, Ironshore Pharmaceuticals Inc., has appointed Craig S. Lewis to the position of President, reporting directly to the IPA Board of Directors. Prior to that, Mr. Lewis served as the Senior Vice President, Global Business Insi
Chugai Pharmaceutical Co., Ltd. announced today that the data from hemophilia A patients who participated in a Phase I study of the bispecific antibody emicizumab was published online in The New England Journal of Medicine on May 25, 2016. The study results had been presented at the 56th American Society of Hematology Annual Meeting held in San Fra
Evan Unger, MD, President and CEO of NuvOx Pharma, a Tucson based biotechnology company, announced that the company has been awarded a grant from the National Cancer Institute to develop an ultrasound contrast agent to diagnose pancreatic cancer. The Phase I Small Business Technology Transfer grant is a joint development project between NuvOx and
Its the latest in a string of drug development companies co-founded by Butts, this time with partners Bill Wofford, Michael Ackermann, Ph.D., MBA, and Stanford University sleep specialist Jed Black, M.D. Then, a few short years after starting Aerial, the founders sold the companys clinical-stage narcolepsy drug to Ireland- based Jazz Pharmaceutical
The leading global contract research and manufacturing firm ABL, Inc. has made an announcement on its settlement of deals with the major biotechnology sector player Regenxbio, Inc., for the production of its lead product RGX-501 intended for clinical trials on human beings. The ABL President& CEO Thomas VanCott, Ph.D. revealed, We are delighted to
By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventors Bagchi, Saumitra; Vuppala, Murali K., filed on October 29, 2015, was made available online on May 12, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a
"Pharmaceutical Composition for Treating Disease Associated with Demyelination of Neurons and Method of Using the Pharmaceutical Composition" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Lee, Yunil; Chang, Kiyoung; Park, Sangchul; Cho, Sungchun, filed on November 5
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Jennings, Robert N.; Ong, John T.H.; Rhodes, Christopher A.; Stetsko, Gregg; Prestrelski, Steven J., filed on October 30, 2015, was made available online on May 12, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents.
By a News Reporter-Staff News Editor at Drug Week The Food and Drug Administration's Office of Hematology and Oncology Products, in co-sponsorship with the Critical Path Institute's Patient-Reported Outcome Consortium, is holding a public meeting titled "Workshop on Clinical Outcome Assessments in Cancer Clinical Trials" on Tuesday, April 26, 7:3
AbbVie, a global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for HUMIRA for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids or in
MALVERN, Pa., May 27, 2016 Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, announced today that it has entered into a stock purchase agreement with a group of institutional accredited investors for the private placement of 1,081,082 shares of common stock at a purchase price of $18.50 per share, yielding expected g
Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.
By a News Reporter-Staff News Editor at Health& Medicine Week Ampio Pharmaceuticals, Inc. announced that patient dosing has begun in the initial clinical trial of Ampion? for the treatment of pain due to osteoarthritis of the hand. Michael Macaluso, Ampio's CEO, noted: "The World Health Organization has determined that Osteoarthritis will be th
AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500 mg to Arimidex 1 mg for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive breast cancer. Sean Bohen, Executive Vice President, Global...
AstraZeneca today announced positive results from the Phase III FALCON trial comparing fulvestrant 500 mg to anastrozole 1 mg for the treatment of locally-advanced or metastatic breast cancer, in postmenopausal women who have not had prior hormonal treatment for hormone receptor positive breast cancer. 1. Fulvestrant 500 mg demonstrated superiority
Victoria is a world-leading location for the development and manufacture of medical technologies, biotechnologies and pharmaceuticals with one-third of Australian clinical trials activity taking place in Victoria. Victoria is also home to more than 180 biotech companies, ten major medical research institutes, ten major teaching hospitals and nine..
-Aviragen Therapeutics, Inc., a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily decided to delay further enrollment in the Phase 2 a trial of BTA585 for the treatment of RSV infections being conducted in the U.K. This decision emanated from a lab report from one subject showing an
ALEXANDRIA, Va., May 27 Berry Pharmaceuticals, Georgetown, Texas, has been assigned a patent developed by Don Wayne Berry, Georgetown, Texas, for a "topical treatment of keratotic lesions using hamelia patens." The patent application was filed on Feb. 12, 2014. Written by Kusum Sangma; edited by Jaya Anand.